|
Overview |
Product information |
Accredo services |
Contact team
Naglazyme is the first specific treatment for MPS VI (mucopolysaccharidosis VI). Naglazyme treats MPS VI by replacing the enzyme that is lacking, arylsulfatase B. Naglazyme reduces the excess carbohydrates—glycosaminoglycans (GAG)—that build up in cells and cause the symptoms of MPS VI. Naglazyme has been shown to improve walking and stair-climbing capacity. Learn more about our MPS VI therapy management.
For more information, please visit Naglazyme.com, or download the full prescribing information.
Referrals
Other Resources:
BioMarin
MPSVI.com
National MPS Society
Naglazyme is a trademark of BioMarin Pharmaceutical Inc.
| 
